Wells Fargo raised the firm’s price target on Argenx (ARGX) to $723 from $639 and keeps an Overweight rating on the shares. The firm adjusted price targets in the Smid-cap biotechnology group as part of its 2025 outlook. Wells top sector picks target Ascendis Pharma (ASND), aTyr Pharma (ATYR), Rhythm Pharmaceuticals (RYTM), and Xencor (XNCR).
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx price target raised to EUR 740 from EUR 620 at JPMorgan
- Argenx price target raised to EUR 670 from EUR 650 at Barclays
- Argenx price target raised to $706 from $675 at Evercore ISI
- Argenx price target raised to $675 from $646 at Oppenheimer
- Argenx may have first targeted myositis treatment, says H.C. Wainwright
Questions or Comments about the article? Write to editor@tipranks.com